Company overview
- Sector
- Pharmaceuticals, Healthcare & Life Sciences
- Sub-sector
- Pharmaceuticals
- Mandate (derived)
- Sales, Marketing & BD
- Parent headquarters
- Mumbai, Maharashtra, India
- Parent revenue (USD)
- $6,200,000,000
- Parent headcount
- 12,714
- India headcount
- Not disclosed
GCC locations
- Mumbai
- Bengaluru
- Baroda
Department mix
Global department counts, used as a proxy for the India mandate. These are not India team counts.
Technology stack
- .GIS
- .NET
- 24-7 Media
- 3M 360 Encompass - Health Analytics Suite
- ABAP
- AC500 PLC
- AI
- AMP
- ANGEL LMS
- AT Internet
- AT&T
- AVEVA Historian
- AVEVA InTouch HMI
- AVEVA PDMS
- AVImark Rapport
Public leadership
Abdulgafur Mir
Vice President Business Finance
Public leadership listed in the dataset; the role is not necessarily the India GCC head.
Research overview
Sun Pharmaceutical Industries Ltd. is India's largest pharmaceutical company and the world's fourth-largest specialty generic pharma company, founded in 1983 by Dilip Shanghvi and headquartered in Mumbai. It manufactures formulations and APIs across psychiatry, cardiology, oncology, dermatology and ophthalmology, operates roughly 41 manufacturing facilities, and sells in about 80 countries with roughly 70% of revenue from international markets.
- India launch
- 1983
- Maturity
- Mature / Integrated Corporate Function
Sun Pharma is a 40+ year old, India-headquartered global generics and specialty pharma major with long-established multi-city presence (Mumbai HQ, Bengaluru, Baroda). No public evidence found of a formally branded GCC/GBS entity distinct from the parent - reads as a mature, deeply embedded internal capability function rather than a classic MNC-style GCC.
Timeline
- 1983
Sun Pharmaceutical Industries founded by Dilip Shanghvi in Mumbai, starting with five psychiatry products.
- 2014
Acquired Ranbaxy Laboratories in an approximately $4 billion all-stock deal, making Sun Pharma India's largest pharmaceutical company.
- 2024
Completed full merger of Taro Pharmaceutical Industries into Sun Pharma (~$347.73 million transaction).
News and developments
Sun Pharma completes acquisition of Organon & Co.
Sun Pharma agreed to acquire Organon & Co. in an approximately $11.75 billion transaction, one of the largest deals in its history.
2026 Wikipedia ↗
Sun Pharma completes merger of Taro Pharmaceutical Industries
Full merger/buyout of long-time subsidiary Taro Pharmaceutical Industries for approximately $347.73 million.
2024 Wikipedia ↗
Sun Pharma reports Q1 FY27 financial results
Quarterly financial results announcement.
2026-07-31 Sun Pharma Media/Press ↗
Sources
Sources and research notes
Source: Indian GCC 2026 Master Compendium, Company Master and research records. Sector, mandate and public leadership are derived fields. Missing values are shown as not disclosed. Revenue and global headcount describe the parent company, not the India centre.